UNION therapeutics to present at the 7th Annual Evercore Healthcare Conference
Hellerup, Denmark, December 4, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that Dr. Kim Kjøller, CEO of UNION […]
UNION therapeutics to present at the 8th Annual Dermatology Drug Development Summit in Boston
Hellerup, Denmark, November 7, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that Dr. Kim Kjøller, CO-CEO of UNION […]
UNION therapeutics announce results from the ADESOS Phase 2b study in atopic dermatitis confirming the potential of orismilast as a first-in-class safe and efficacious oral treatment
Orismilast Phase 2b results in atopic dermatitis (AD) presented today as a late-breaking oral presentation at the European Academy of Dermatology and Venerology (EADV) Congress 2024 Orismilast demonstrated clear treatment […]
UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis as a late-breaking oral presentation at the EADV Congress 2024
ADESOS Phase 2b results with orismilast in atopic dermatitis (AD) selected as late-breaking oral presentation Additionally, two posters on data from the pioneering use of tape stripping for biomarker analysis […]
UNION therapeutics appoints drug development leader Dr. Peter Kristensen to its Board of Directors
Dr. Peter Kristensen, MD, DMSc, EMBA, appointed new member of UNION’s Board of Directors, bringing more than 25 years of expertise from drug development and regulatory approval from pharmaceutical companies […]
UNION therapeutics announces successful completion of the ADESOS Phase 2b study and presentation of data at the RAVE Conference 2024
ADESOS Phase 2b study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe atopic dermatitis (AD) has successfully completed Results from the ADESOS study have been selected […]
UNION therapeutics announces publication of results from the OSIRIS Phase 2 study of orismilast in hidradenitis suppurativa in the Journal of the European Academy of Dermatology and Venereology
Orismilast demonstrated clinically relevant improvements in patients with hidradenitis suppurativa (HS), confirming the relevance of orismilast for the treatment of HS 67% of patients completing 16 weeks of treatment achieved […]
UNION therapeutics announces full-year results for 2023
Hellerup, Denmark, February 7, 2024, – UNION therapeutics A/S (“UNION”), a privately held, clinical stage, pharmaceutical development company focused on immunology, announces full-year results for the period January 1 to […]
UNION therapeutics to present at the 42nd Annual J.P. Morgan Healthcare Conference
Hellerup, Denmark, January 5, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that Dr. Kim Kjøller, CEO of UNION […]
UNION therapeutics announces enrollment of the first patient in the UCORIS Phase 2 IIT study of orismilast in patients with ulcerative colitis
UCORIS is an investigator-initiated, Phase 2 study of orismilast for the treatment of moderate to severe ulcerative colitis (UC) UC is a chronic, inflammatory bowel disease with substantial unmet […]
